The aim of this study was to determine whether parameters related to TBI impacted upon OS and relapse in patients with acute leukemia in CR who underwent haematopoietic SCT (HSCT) in 11 Italian Radiation Oncology Centres. Data were analysed from 507 patients (313 males; 194 females; median age 15 years; 318 with ALL; 188 with AML; 1 case not recorded). Besides 128 autologous transplants, donors included 192 matched siblings, 74 mismatched family members and 113 unrelated individuals. Autologous and allogeneic transplants were analysed separately. Median follow-up was 40.1 months. TBI schedules and HSCT type were closely related. Uni- and multi-variate analyses showed no parameter was significant for OS or relapse in autologous transplantation. Multivariate analysis showed type of transplant and disease impacted significantly on OS in allogeneic transplantation. Disease, GVHD and TBI dose were risk factors for relapse. This analysis illustrates that Italian Transplant Centre use of TBI is in line with international practice. Most Centres adopted a hyperfractionated schedule that is used worldwide (12 Gy in six fractions over 3 days), which appears to have become standard. TBI doses impacted significantly upon relapse rates.

In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study / Aristei, C; Santucci, A; Corvò, R; Gardani, G; Ricardi, U; Scarzello, G; Magrini, Sm; Donato, V; Falcinelli, L; Bacigalupo, A; Locatelli, F; Aversa, Franco; Barbieri, E.. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - 48:7(2013), pp. 908-914. [10.1038/bmt.2013.66]

In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study

AVERSA, Franco;
2013-01-01

Abstract

The aim of this study was to determine whether parameters related to TBI impacted upon OS and relapse in patients with acute leukemia in CR who underwent haematopoietic SCT (HSCT) in 11 Italian Radiation Oncology Centres. Data were analysed from 507 patients (313 males; 194 females; median age 15 years; 318 with ALL; 188 with AML; 1 case not recorded). Besides 128 autologous transplants, donors included 192 matched siblings, 74 mismatched family members and 113 unrelated individuals. Autologous and allogeneic transplants were analysed separately. Median follow-up was 40.1 months. TBI schedules and HSCT type were closely related. Uni- and multi-variate analyses showed no parameter was significant for OS or relapse in autologous transplantation. Multivariate analysis showed type of transplant and disease impacted significantly on OS in allogeneic transplantation. Disease, GVHD and TBI dose were risk factors for relapse. This analysis illustrates that Italian Transplant Centre use of TBI is in line with international practice. Most Centres adopted a hyperfractionated schedule that is used worldwide (12 Gy in six fractions over 3 days), which appears to have become standard. TBI doses impacted significantly upon relapse rates.
2013
In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study / Aristei, C; Santucci, A; Corvò, R; Gardani, G; Ricardi, U; Scarzello, G; Magrini, Sm; Donato, V; Falcinelli, L; Bacigalupo, A; Locatelli, F; Aversa, Franco; Barbieri, E.. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - 48:7(2013), pp. 908-914. [10.1038/bmt.2013.66]
File in questo prodotto:
File Dimensione Formato  
Aristei BMT 2013.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 488.38 kB
Formato Adobe PDF
488.38 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2677880
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 15
social impact